DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS
肠胃外剂型的开发和生产
基本信息
- 批准号:2840597
- 负责人:
- 金额:$ 136.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-30 至 2002-09-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The primary objective of this project is to develop and produce
Pharmaceutically acceptable parenteral dosage forms of promising new
agents with activity against cancer or the HIV virus. Certain agents
selected by the NCI, DCTDC, Cancer and AIDS operating committees
will be assigned for development and production as parenteral
products (primarily sterile freeze dried products). Batch sizes will
range from small development batches (less than 100) to intermediate
size batches to be used in Phase I and II trials; however, escalation to
large batch Size (10-30,000 or more) for Phase III/IV trials and Group
C distribution is possible. It is estimated that the successful offerors
must be prepared to supply more than five-hundred thousand
parenteral dosage units each year. The capability to develop and
manufacture other pharmaceutical dosage form (i.e. large volume
parental, sterile emulsions, sterile micro-dispersions, etc) is desirable
but not essential. Data obtained from the contract will: 1) be used to
support IND applications submitted by the National Cancer Institute
to the U.S. Food and Drug Administration, 2) be provided to other
NCI contractors engaged in large scale dosage form manufacture and
analytical evaluation of these dosage forms and 3) be provided to
physicians, pharmacists, and nurses and other medical personnel
handling these products in a clinical setting.
这个项目的主要目标是开发和生产
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIMOTHY D SMITH其他文献
TIMOTHY D SMITH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIMOTHY D SMITH', 18)}}的其他基金
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS
肠胃外剂型的开发和生产
- 批准号:
2662838 - 财政年份:1997
- 资助金额:
$ 136.73万 - 项目类别:
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS
肠胃外剂型的开发和生产
- 批准号:
6356122 - 财政年份:1997
- 资助金额:
$ 136.73万 - 项目类别:
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS
肠胃外剂型的开发和生产
- 批准号:
6094661 - 财政年份:1997
- 资助金额:
$ 136.73万 - 项目类别:
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS
肠胃外剂型的开发和生产
- 批准号:
6355502 - 财政年份:1997
- 资助金额:
$ 136.73万 - 项目类别:
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS
肠胃外剂型的开发和生产
- 批准号:
2300407 - 财政年份:1992
- 资助金额:
$ 136.73万 - 项目类别:
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS
肠胃外剂型的开发和生产
- 批准号:
2300406 - 财政年份:1992
- 资助金额:
$ 136.73万 - 项目类别:
PRODUCTION OF CLINICAL DOSES OF ANTITUMOR AGENTS
抗肿瘤药物临床剂量的生产
- 批准号:
3614884 - 财政年份:1987
- 资助金额:
$ 136.73万 - 项目类别:
PRODUCTION OF CLINICAL DOSES OF ANTITUMOR AGENTS
抗肿瘤药物临床剂量的生产
- 批准号:
3614885 - 财政年份:1987
- 资助金额:
$ 136.73万 - 项目类别:
DEVELOP AND PRODUCE DOSAGE FORMS OF ANTI-AIDS AGENTS
抗艾滋病剂剂型的开发和生产
- 批准号:
3614279 - 财政年份:1986
- 资助金额:
$ 136.73万 - 项目类别:
DEVELOP AND PRODUCE DOSAGE FORMS OF ANTI-AIDS AGENTS
抗艾滋病剂剂型的开发和生产
- 批准号:
3614282 - 财政年份:1986
- 资助金额:
$ 136.73万 - 项目类别:
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 136.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 136.73万 - 项目类别:
Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6623455 - 财政年份:2002
- 资助金额:
$ 136.73万 - 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6465958 - 财政年份:2002
- 资助金额:
$ 136.73万 - 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
- 批准号:
6483914 - 财政年份:2002
- 资助金额:
$ 136.73万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6124630 - 财政年份:1998
- 资助金额:
$ 136.73万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6329037 - 财政年份:1998
- 资助金额:
$ 136.73万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
2747737 - 财政年份:1998
- 资助金额:
$ 136.73万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459680 - 财政年份:1990
- 资助金额:
$ 136.73万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459678 - 财政年份:1990
- 资助金额:
$ 136.73万 - 项目类别: